Search Main Menu Main Content
  • Change contrast :
Retour à l'accueil du site de la HAS
logo HAS
Développer la qualité dans le champ sanitaire, social et médico-social
Logo
  • HAS profile
    • Mission
    • Organisational Structure
    • Ethics, transparency and management of conflicts of interest
  • International relations and projects
  • Publications
  1. root
  2. TABRECTA (capmatinib)
  • icone plus
  • My account

    • Email alert Subscription
    • Newsletter Subscription
    • My search
    Refresh
    Please fill in your email address to retrieve your email alerts subscriptions.
    New subscription
    Please fill in your email address to retrieve your newsletter subscriptions.

    You do not have a saved search

    Mon Compte
  • Établissements de santé
Add to my selection
  • History
  • Technical informations
Share
Share on
Facebook share - facebook.com - new window
Tweeter share - Partager sur Twitter - twitter.com - new window
LinkedIn share - linkedin.com - new window
Print

TABRECTA (capmatinib)

Medicine - Posted on Jan 20 2023
Active substance (DCI)
  • capmatinib
history (2)
  • 1/18/23

    TABRECTA (capmatinib) - Cancer bronchique non à petites cellules (CBNPC)

    Key points Disapproval of reimbursement for adult patients with advanced non-small cell lung cancer (NSCLC) presenting with ...
    CAV :
    54321
    icône flèche
  • 7/13/22

    TABRECTA (capmatinib) - cancer bronchique non à petites cellules (CBNPC)

    Autorisation d’accès précoce refusée à la spécialité TABRECTA (capmatinib) dans l’indication « en monothérapie pour le trait...
    icône flèche
Technical information
ATC code
  • L01EX17
Manufacturer
NOVARTIS PHARMA SAS
Presentation

TABRECTA 200 mg, comprimé pelliculé
Boite de 120 comprimés (CIP : 34009 302 533 4 2)

TABRECTA 150 mg, comprimé pelliculé
Boite de 120 comprimés (CIP : 34009 302 533 3 5)

All our publications
    Drug therapy Respiratory tract cancers

Follow us :

  • Twitter (nouvelle fenêtre)
  • Facebook (nouvelle fenêtre)
  • Youtube (nouvelle fenêtre)
  • LinkedIn (nouvelle fenêtre)
Haute Autorité de Santé
Advancing quality in the fields of health and social care services
  • Eunetha.eu
  • Pasq.eu
  • All our publications by topic and type
  • Opinions on medicines
  • Opinions on medical devices
  • INAHTA briefs
  • Français
  • English
eNq1mNty2jAQhu95Co8veofNMUBrYFqatMwkU0pg2ukNI9tLEDWSowOHPn1lDA3pyJNEoEss+9/17urTj4P+dpU4a2AcU9J1q17FdYBENMbkoetOJzflttvvlYIlWqOT21pexavWXCdKEOddN1v1QkCEez/vbj+Deh6Y2ys5AQ2XEIln90mBE+8r4os7lGb3OMGa4thZgVjQuOumUuyvOgEXTGXR21D2m6cogsA/XDldXc4ap9cDPxN7harkwG4RedCKAjHSjCRjQMQACXigbFeQb91IG/MxcCpZBCMkFiNG1ziGWBtijhIORkHmm/ge2DoBkQXRivvLaMWNxNESbcfwONQn/VGtDsRWlCvlaqvVbFRa7Ua7VmsZhWInpdJ3Qb2En87q9Wbn6qrjA/EFCpmaVFSOULpCAhMcGvZpRJlAiaUOYT54PmSW4jB4fHESYszTBO28JU9NS4UYUsvAFArsvUj2BhOm4JSomv2nT2SS+G/MenpAh6WMMzINqCSigCA3Y9NCDCgRsC3uqBn0xPYwixj45WT/UKIH/kiGCY5M8aYAJIGL6XhYTDdbYPiEOEyZPTL8wCSmG3554px22FL26R6aWtGUxdVZrdO+qjabxhvqlxqngpPnWjKagq9YhPk5iBmSOT0XLmpC9VLH+bQymnsvRCOUQIEbKhsyR83k0bxZm3p7Oypf0Ip+uZ6Yjsp3CWx3v/+plcZx91+TzYBsg/JqMF9KPN/CWfKVZrtTb7xDq/TD0WZ3DS11LmrFUUum581CiJS/9/3NZuMtEC9zpOrpzdnrzoa+tgyXKIUC8VNn7f0BsGISctOUQ9hS6mF+ur6tpaab+CUbca41Pjx/sODaGIJJOKMXOe+tUXl4fXnQP/lia2mPnuHGXpi9h1XAoMSWn5KhHtJnHS2qr+SGKUB8m89xwQeZwrkM/PxjUK8U+NmHoF7pLynjE3Q=
a9HPJUbnC2yCufgr